Corey J. Langer

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Carboplatin plus pemetrexed versus pemetrexed alone in advanced thymoma and thymic carcinoma: a retrospective cohort study

  Frontiers in Oncology · 2026-04-22

• Real World Radiographic Response Rates and Preoperative Attrition in Patients With Non–Small Cell Lung Cancer (NSCLC) Treated With Neoadjuvant Chemoimmunotherapy

  American Journal of Clinical Oncology · 2025-11-07 · 1 citations

• The influence of body mass index on Tumor Treating Fields therapy in patients with metastatic non-small cell lung cancer: A post-hoc and simulation analysis from the phase III LUNAR study

  Lung Cancer · 2025-10-21

• PL02.18 Phase 3 Trial of Crizotinib vs Observation for Surgically Resected Early-Stage ALK+ NSCLC

  Journal of Thoracic Oncology · 2025-10-01 · 1 citations

• First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study

  The Lancet Oncology · 2025-10-01 · 7 citations

• Phase II Study of Low-Dose Paclitaxel and Cisplatin in Combination With Split-Course Concomitant Twice-Daily Reirradiation in Recurrent Squamous Cell Carcinoma of the Head and Neck: Long-term Follow-up of NRG Oncology RTOG 9911

  International Journal of Radiation Oncology*Biology*Physics · 2025-07-31 · 1 citations

• Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non–Small-Cell Lung Cancer According to ALK Fusion and Mutation Status

  Clinical Lung Cancer · 2025-06-05 · 1 citations

• First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors for patients with BRAF ^V600E -mutated metastatic non-small cell lung cancer: The FRONT-BRAF study.

  Journal of Clinical Oncology · 2025-05-28 · 2 citations

• Survival after osimertinib dose-reduction, discontinuation in 1L <i>EGFR</i> -mutated metastatic non-small cell lung cancer (mNSCLC).

  Journal of Clinical Oncology · 2025-05-28

• EMBER-Lung: Electronic medical record boosting molecular testing in early stage NSCLC.

  Journal of Clinical Oncology · 2025-05-28

• Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLC

  JTO Clinical and Research Reports · 2025-05-26 · 2 citations

• Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis

  Lung Cancer · 2025-04-19 · 5 citations

• Incidence and Outcomes of Brain Metastasis in Pleural Mesothelioma in the Era of Immunotherapy

  JTO Clinical and Research Reports · 2025-03-10

• Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy

  Clinical Lung Cancer · 2024-12-13 · 3 citations

• Outcomes Following Treatment for Progression in Patients Treated With Durvalumab Consolidation in LA-NSCLC

  Clinical Lung Cancer · 2024-11-10 · 3 citations

• OA06.04 Phase II Study of Pembrolizumab and Itacitinib for Patients with Metastatic NSCLC Expressing PD-L1: Long-Term Follow up

  Journal of Thoracic Oncology · 2024-10-01 · 1 citations

• P3.06D.06 Incremental Value of Liquid Biopsy in the Initial Evaluation of Non-Small Cell Lung Cancer Patients Undergoing Tissue Based Molecular Testing

  Journal of Thoracic Oncology · 2024-10-01

• Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) treated with osimertinib (osi) vs. Afatinib or erlotinib

  Lung Cancer · 2024-08-10 · 3 citations

• Predictive Signatures for Responses to Checkpoint Blockade in Small-Cell Lung Cancer in Second-Line Therapy Do Not Predict Responses in First-Line Patients

  Cancers · 2024-08-08 · 2 citations

• Calls to action on lung cancer management and research

  The Oncologist · 2024-07-13 · 3 citations